Bactiguard coated Foleys show significant reduction in symptomatic urinary tract infections

A recently published clinical  study* from the United States, concludes that Bactiguard coated Foley catheters significantly reduce symptomatic catheter associated urinary tract infections (CAUTI) and use of antibiotics. A 47-58 percent reduction of CAUTI and a 60 percent relative reduction of antibiotic use were recorded.

This non-randomized before-after cohort study included seven acute care hospitals in the United States. The hospitals had previously used standard catheters and then switched to Bactiguard-coated Foley catheters (Bardex I.C). In total, 853 patients wre included in the study, with 453 and 400 patients in the standard- and the coated Foley catheter group, respectively.

In this study, both a clinical definition of symptomatic CAUTI and the revised US Center of Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) definitions of CAUTI were used. The revised CDC definition excludes asymptomatic bacteriuri and includes only symptomatic CAUTIs.

The results of the study show that the use of Bactiguard coated Foley catheters is associated with a significant reduction in CAUTI rates. A 47 percent relative reduction was found using both CDC and clinically defined CAUTI definitions, and a 58 percent relative reduction occurred when only CDC definitions were considered. Furthermore, a 60 percent relative reduction of antibiotic use was recorded for patients using Bactiguard coated Foley catheters.

“This is an important study, as it confirms that the use of Bactiguard coated Foleys can significantly reduce both symptomatic urinary tract infections and the use of antibiotics. This is very encouraging given the rapidly increasing problem of healthcare associated infections and antimicrobial resistance world wide,” says Johan Rugfelt, CEO of Bactiguard.

*Lederer et al. J Wound Ostomy Continence Nurs. 2014 Jun 11.
Multicenter Cohort Study to Assess the Impact of a Silver-Alloy and Hydrogel-Coated Urinary Catheter on Symptomatic Catheter-Associated Urinary Tract Infections.

Link to article in PubMed:
http://www.ncbi.nlm.nih.gov/pubmed/24922561

For further information, please contact:

Johan Rugfelt, CEO

johan.rugfelt@bactiguard.se

Switchboard: +46 8 440 58 80


Cecilia Edström, Director of Communications

cecilia.edstrom@bactiguard.se

Mobile: +46 722 262 328

Bactiguard
Bactiguard is a Swedish medtech company with a mission of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions to the healthcare industry. The company’s patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of coated catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the EU, Middle East, Asia and South America. The company reported  sales of approximately SEK 130 million in 2013, has 60 employees, headquarters in Stockholm and production facilities in Markaryd and Malaysia. 

Tags:

About Us

Bactiguard is a Swedish medtech company with a global presence, offering a solution that prevents healthcare associated infections caused by medical devices. By preventing infections, we contribute to a reduced use of antibiotics and the spread of multi-resistant bacteria, which is a growing problem worldwide. We save lives, increase patient safety and significantly reduce the cost for the healthcare and society. Our technology is well-proven, safe and tissue friendly and consist of a thin layer of noble metals that prevents bacterial growth. The coating can be applied on almost all medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan and the company has also its own product portfolio consisting of foley catheters, central venous catheters and endotrachealtubes. Bactiguard is a growth company, focused on markets in Europe, Middle East, Asia and Latin America. The company has about 70 employees worldwide, mainly at the headquarters in Stockholm and the production facility in Malaysia and is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com

Subscribe

Documents & Links

Quotes

“This is an important study, as it confirms that the use of Bactiguard coated Foleys can significantly reduce both symptomatic urinary tract infections and the use of antibiotics. This is very encouraging given the rapidly increasing problem of healthcare associated infections and antimicrobial resistance world wide,”
Johan Rugfelt, CEO Bactiguard